Immupharma Share Discussion Threads

[wildbunch] 22/1/2018 19:39

njb67 How many more times are you going to say the same things? Of course we must build this negative stuff in to our risk reward calculations. Those of us that bought early (I average 45p) are better placed that latecomers. That to is obvious. So I will not repeat it!

[njb67] 22/1/2018 19:30

jp
No on both counts. Just trying to discuss one of the very real risks with IMM and all small pharma cos. If IMM get a positive FDA approval on the back of the phase 3 study, result! You do though need to work through what would happen if they do not get FDA approval as they do not have the money for a second phase 3 study nor company overheads beyond mid 2019 at best.

[jp1962] 22/1/2018 19:22

Your post is clearly leaning towards a deramping stance in my opinion and smacks of someone wanting in cheaper having sold in my opinion.If the drug is approved then the costs you mention are small compared to the huge resulting share price increase.A placing could be done at a much higher share price.The ceo was very optimistic given patients wanted to continue the treatment!

[njb67] 22/1/2018 19:16

Dav - agreed. The buy/sell data can be very misleading, especially delayed trades.

On financing, IMM have enough cash to complete the phase three study and cover the corporate overheads until the end of 2018. The cash burn on overheads is around £1.5m per annum, so the extra £600k mentioned by Long (if not already included in their own figures) is a another 5 months.

If IMM do not get FDA approval with one phase 3 study, then they will need to fund raise, both for the second ph3 study and the company overheads. In my experience this will be more difficult and expensive than previous fund raising activities, with question marks about the commercial value and viability of Lup and the P140 platform. It will be severely dilutive to existing holders. This is a real financial risk, something the ramping gang never reference. While you may not like what I am saying and some will no doubt accuse me of having an agenda, I would really encourage you to do your own research. This is biotech - it is high risk business - and even more so for a company with no approved medicine or revenues.

One final comment. Do not underestimate how much it will cost IMM in legal and advisor fees for any licensing or sale agreement. These will run into millions.

Still hold and here for the ride.

GLA

[davr0s] 22/1/2018 19:14

I'm not even sure it's MM. Computer tries to work out buys and sells by where the trade happened wrt to bid and ask price. And even then it gets it wrong. Also big buyers and sellers can take days to report and the computer guesses the trade at the time the trade is reported so it often gets that wrong too. It sometimes gets it right but it's a guess. Unless you are a day trader your looking too closely if you are trying to interpret trades going through

[btfd497] 22/1/2018 19:12

The 140,000 trade today was a sell, that’s why it shot down. Will be one of the big boys topslicing.

[ytsa2] 22/1/2018 19:07

Is that 100% correct. More buyers up, more sellers down. MMs can manipulate price when they want?

[davr0s] 22/1/2018 18:39

I've posted (and others have too) that you can't work out buys and sells - you simply can't. This has been known for years. But people still think they can and tie themselves in knots as a result. If price goes up there are more buyers and down more sellers. This is a largely binary outcome - a much higher price or a much lower price. All the wobbling about in the meantime is noise. If people getting stressed then their position size is too high

[dontshoutatonce] 22/1/2018 18:19

Those ruddy mms have been making small havoc for the last week and especially today, causing the drop (in my opinion) and some stop losses and others to trigger sells, so fair to assume them to let the price hike tomorrow now they've got their oar in and it may, may just soar? Interesting to watch. Thoughts please?

[aussieb3] 22/1/2018 18:07

It's not that's its volitle. people are annoyed because they can see more buys and then it's going down . Just frustration

[davr0s] 22/1/2018 17:59

Crikey a bit of volatility and people get into a frenzy. Guess what it's a volatile share - get used to it!

[ny boy] 22/1/2018 17:55

Yes a placing at this stage, makes no sense imho, just the LSE boys being a tad mischievous

[wossupsa] 22/1/2018 17:48

Can see why some think a placing might be happening as there has been so much selling since the last RNS, opportunistic or not would be the question?

[che7win] 22/1/2018 17:45

Are you serious?It was dismissed last July when they said they had funding to end of 2018.

[dontshoutatonce] 22/1/2018 17:37

kfp, I could afford many naughty, squeaky girls, but after blowing them up I wouldn't have the puff for anything else.

[l0ngterm] 22/1/2018 17:37

A placing would not really be achievable before publishing the results. Any II or private investor would be sceptical to say the least. The reasoning being the investor would ask "tell me the results" if not then "No", why take the risk? The company can't state the results because that has to be released to the market, so really can't see this at all.

[kfp] 22/1/2018 17:34

NY Boy
Of course ! when the share price get's to £100 I can buy a Chemist shop !

[ny boy] 22/1/2018 17:29

Kfp, I heard there are drugs available to assist 😉

[ny boy] 22/1/2018 17:22

Someone could email Tim and ask him if he can dismiss the placing issue speculation mentioned on LSE

[kfp] 22/1/2018 17:18

sportbilly1976

Could be the trade that knocked the price in the first place ?

[kfp] 22/1/2018 17:14

minky

£100 per share would mean I can afford a naughty girl but unfortunately at my age I wouldn't know what to do with her !!

[l0ngterm] 22/1/2018 17:04

To clarify the status: 10th of March 2017 4.1 million raised, this was to support partner discussions, not the trial. The company only has 10 employees if that and not all full time, and a burn prior to trials of under a million(from memory).Subsequently received a further 600k due to the nature of the lanstead deal. Trial fully funded: 2016. 9.4 million to cover trials operations. On 10 March 2017, the Company announced the completion of a placing of 7,884,623 new ordinary shares of 10p each at a placing price of 52p raising a total of GBP4.1 million before expenses. The shares are EIS and VCT qualifying. Major existing and new institutional investors participated in the New Share Placing. The Company raised the funds in order to further strengthen the Company's Statement of Financial Position as negotiations continue with potential partners for Lupuzor(TM) and to support further investment in ImmuPharma's earlier stage portfolioTim McCarthyNon-Executive ChairmanImmuPharma plcFinancial Review2016 was a year focused on strengthening ImmuPharma's financial position and progressing our lead programme, Lupuzor(TM) , and its pivotal Phase III trial. Two successful placings were completed in 2016; the first, completed in February/March 2016, was a GBP8.4 million placing and subscription before expenses, and the second was completed in October 2016 raising a further GBP1 million before expenses as part of a GBP3.5 million vendor placing for a total of GBP9.4 million before expenses. In addition, in March 2017, we completed a successful third funding round of GBP4.1 million before expenses

[aussieb3] 22/1/2018 16:56

Wow 140000 trade probably a buy someone buying these up cheap . Instead making them pay a higher price they keep lowering it allowing them to get more shares. Mm how do u sleep at night